Variable | Ratio | Without interaction termsa | With interaction terms | |
---|---|---|---|---|
 |  |  | Maximum likelihood estimate (± standard error) | Wald χ2 (probability > χ2) |
Overall treatment success | Â | Â | Â | Â |
   ICU statusb | Not in ICU to in ICU | 1.866 (1.147 to 3.034) | 0.1380 ± 0.5438 | 0.0644 (0.7997) |
   Persistent neutropenia | Non-neutropenic to neutropenic | 5.721 (1.412 to 23.169) | 1.7185 ± 0.7156 | 5.7669 (0.0163) |
   APACHE II score | High to low (continuous) | 0.956 (0.929 to 0.983) | --0.0468 ± 0.0144 | 10.6416 (0.011) |
Mycological response | Â | Â | Â | Â |
   ICU statusb | Not in ICU to in ICU | 1.778 (1.037 to 3.048) | --0.0223 ± 1.7567 | 0.0002 (0.9899) |
   Primary diagnosis | Candidemia to invasive candidiasis | 2.465 (1.343 to 4.524) | 0.3246 ± 0.4368 | 0.5522 (0.4574) |
   Neutropeniab | Non-neutropenic to neutropenic | 2.357 (1.134 to 4.898) | --0.9093 ± 1.0206 | 3.4859 (0.0619) |
   Diabetes mellitus | No to yes | 0.350 (0.137 to 0.894) | --1.0113 ± 0.5362 | 3.5572 (0.0593) |
   APACHE II score | High to low (continuous) | 0.953 (0.925 to 0.982) | --0.0505 ± 0.0154 | 10.7417 (0.001) |
All-cause mortality at day 8 | Â | Â | Â | Â |
   Candida spp. | Candida krusei to other Candida spp. | 3.536 (1.039 to 12.035) | 2.4861 ± 1.3739 | 3.2745 (0.0704) |
   APACHE II score | High to low (continuous) | 1.097 (1.055 to 1.142) | 0.0931 ± 0.0208 | 20.0498 (< 0.0001) |
All-cause mortality at day 30 | Â | Â | Â | Â |
   Age | Low to high | 1.018 (1.003 to 1.033) | 0.0170 ± 0.0076 | 4.9331 (0.0263) |
   Persistent neutropenia | Non-neutropenic to neutropenic | 0.160 (0.039 to 0.658) | --1.7845 ± 0.7146 | 6.2358 (0.0125) |
   APACHE II score | High to low (continuous) | 1.093 (1.057 to 1.131) | 0.0937 ± 0.0178 | 27.7797 (< 0.0001) |